CN107837298A - A kind of sea-buckthorn oil health care product - Google Patents
A kind of sea-buckthorn oil health care product Download PDFInfo
- Publication number
- CN107837298A CN107837298A CN201610828363.3A CN201610828363A CN107837298A CN 107837298 A CN107837298 A CN 107837298A CN 201610828363 A CN201610828363 A CN 201610828363A CN 107837298 A CN107837298 A CN 107837298A
- Authority
- CN
- China
- Prior art keywords
- parts
- sea
- health care
- care product
- seed oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 22
- 230000036541 health Effects 0.000 title claims abstract description 20
- 240000000950 Hippophae rhamnoides Species 0.000 title 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000003921 oil Substances 0.000 claims abstract description 22
- 235000019198 oils Nutrition 0.000 claims abstract description 22
- 241000229143 Hippophae Species 0.000 claims abstract description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 13
- 239000000787 lecithin Substances 0.000 claims abstract description 13
- 235000010445 lecithin Nutrition 0.000 claims abstract description 13
- 229940067606 lecithin Drugs 0.000 claims abstract description 13
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims abstract description 13
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 7
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 5
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 240000000924 Lycium carolinianum Species 0.000 description 1
- 235000015463 Lycium carolinianum Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
There is anti-oxidant, cardiovascular protective effect sea-buckthorn oil health care product the invention discloses a kind of.It is the Purple Perilla Seed Oil to purify Seabuckthorm Seed Oil, lecithin, and vitamin E is prepared for raw material.Sea-buckthorn oil health care product of the invention sea-buckthorn oil health care product without any side effects, of the invention, starts with from old complaint, strengthens the body resistance to consolidate the constitution, by improving lipid-metabolism, so as to improve blood flow etc., the pathogenesis basis of cardiovascular disease is thoroughly cut off, effects a radical cure its recurrence, it is safe and efficient, reach the effect of complex treatment.
Description
Technical field
The present invention relates to a kind of nutrient and healthcare products, specifically a kind of sand with anti-oxidant protection Cardiovascular
Spine oil health care product.
Background technology
In recent years, the illness rate of cardiovascular disease, the incidence of disease and the hazards of cardiovascular disease are caused to be in continuous ascendant trend,
The death rate of China's cardiovascular disease accounts for the 43% of crude death rate according to statistics.Coronary heart disease, miocardial infarction and by the caused rhythm of the heart
Generation, the development of the angiocardiopathy such as not normal, are all precipitated, and form Atherosclerosis with lipid in vascular wall and other organs
Change, and the consequence of generation hemodynamic change is relevant, in addition, the change with dietary structure with the improvement of people ' s living standards, makes
The incidence of disease for obtaining hyperlipidemia is in obvious ascendant trend, in the patient that hospital's medical treatment not only be present, in normal population
As common phenomenon.These people are the huge standby crowds that possible develop into serious cardiovascular and cerebrovascular disease, according to " prevention
Based on " principle, early prevention, early treatment are particularly important.
At present be clinically used for treatment medicine mostly be effect it is single, respectively have weighting, can not fundamentally treat disease and
Suppress the pathogenetic chemicals of disease, such as：Expand the medicines such as blood vessel, softening blood vessel, thrombus, dilute blood, these medicines
There is side effect, it is unsuitable long-term use of.
The content of the invention
It is an object of the invention to from the angle effected a permanent cure, by improving lipid-metabolism, so as to improve blood flow etc., there is provided
A kind of sea-buckthorn oil health care product with protection Cardiovascular.
The sea-buckthorn oil health care product of the present invention is made up of following activated feedstock：Purify Seabuckthorm Seed Oil, Purple Perilla Seed Oil, lecithin
Fat, vitamin E.
The sea-buckthorn oil health care product preferred scheme of the present invention is made up of the activated feedstock of following weight：Purify seabuckthorn seeds
70 ~ 80 parts of oil, 15 ~ 22 parts of Purple Perilla Seed Oil, 3 ~ 4 parts of lecithin, 2 ~ 4 parts of vitamin E.
The sea-buckthorn oil health care product preferred plan of the present invention is made up of the activated feedstock of following weight：Purify seabuckthorn seeds
80 parts of oil, 13 parts of Purple Perilla Seed Oil, 4 parts of lecithin, 3 parts of vitamin E.
The sea-buckthorn oil health care product preferred plan of the present invention is made up of the activated feedstock of following weight：Purify sea-buckthorn
80 parts of seed oil, 15 parts of Purple Perilla Seed Oil, 3 parts of lecithin, 2 parts of vitamin E.
The sea-buckthorn oil health care product of the present invention prepares scheme：Purification Seabuckthorm Seed Oil, lecithin, dimension life are weighed according to the above ratio
Plain E is mixed, and is homogenized the active ingredient compositions that the present invention is made.
By existing manufacture craft, various oral liquids, soft capsule, ready-mixed oil etc. can be processed into.
Seabuckthorm Seed Oil is that one kind contains multivitamin, various trace elements, several amino acids and other biological activity thing
The medicinal food of matter, the serum triglyceride of hyperlipemic patients can be made（TG）And cholesterol（TC）Two kinds of indexs decline, and make blood
Aloof from politics and material pursuits density lipoprotein（HDL）Rise, so as to adjust blood fat, prevents the generation of cardiovascular and cerebrovascular diseases.Lecithin is as biomembrane group
Point, the cholesterol that can be effectively embedding in film, by promoting lipid to circulate, accelerate cholesterol metabolic.Vitamin E can effective ground resistance
The peroxidating of lipid, directly dissolves atheromatous plaque on vascular wall in disconnected blood.
Purple perilla seed, is the medical and edible dual purpose plant that country ratifies in the first batch, and Purple Perilla Seed Oil contains the serial how unsaturateds of abundant ω -3
Aliphatic acid.Wherein alpha-linolenic acid content is up to 70% or so, and having reduces cholesterol in serum, triglycerides, low-density lipoprotein
White and VLDL effect, so as to inhibition thrombosis, prevent the match of cardiac muscle stalk and cerebral infarction is matched, alpha-linolenic acid is also in addition
Blood viscosity can be reduced, increase the synthesis of blood oxygen carrying content, always triglycerides, increase the excretion of various lipids in vivo, institute
It is particularly evident with the effect of Purple Perilla Seed Oil blood fat-reducing blood pressure-decreasing, it is especially more prominent to high fat of blood and borderline hypertension effect.
Seabuckthorm Seed Oil, Purple Perilla Seed Oil, lecithin, vitamin E etc. all have a significant therapeuticing and health effect to angiocarpy, and four
Person, which combines prescription, can realize the synergistic function for having complementary functions and giving full play between component.
The sea-buckthorn oil health care product of the present invention is edible by animal function test and crowd it is demonstrated experimentally that tool has the advantage that：
1st, acute toxicity test and sub-acute toxicity test explanation, sea-buckthorn oil health care product of the invention is without any side effects, symbol
Close requirement and the development trend of health products.2nd, sea-buckthorn oil health care product of the invention is taken by daily, start with from old complaint, righting it is solid
Originally, by improving lipid-metabolism, the blood fat deposited on free vascular wall is dissolved, reduces lipids contents, improves blood transportation oxygen
With the ability of nutriment, the microthrombus of capillary is eliminated, prevents free radical from being formed, so as to thoroughly cut off the hair of cardiovascular disease
Sick basis, effects a radical cure its recurrence, safe and efficient, has reached the effect of complex treatment.
Embodiment
Embodiment 1：Extract pure 70 parts of Seabuckthorm Seed Oil, 22 parts of Purple Perilla Seed Oil, 4 parts of lecithin, 4 parts of mixing of vitamin E stir
Mix, be homogenized the active ingredient compositions that the present invention is made.
Embodiment 2：Extract pure 80 parts of Seabuckthorm Seed Oil, 15 parts of Purple Perilla Seed Oil, 3 parts of lecithin, 2 parts of mixing of vitamin E stir
Mix, be homogenized the active ingredient compositions that the present invention is made.By existing soft capsule production technology filling capsule, bottling, through cobalt60Width
According to sterilizing, it is packaged into box and sea-buckthorn oil health care product soft capsule is made.Every 1g containing active ingredient compositions of capsule, instructions of taking：
It is daily 2-3 times, each 1-4 grains.
Claims (3)
1. a kind of sea-buckthorn oil health care product, it is characterised in that it is made up of the activated feedstock of following weight：Purify seabuckthorn seeds
70 ~ 80 parts of oil, 25 ~ 13 parts of Purple Perilla Seed Oil, 3 ~ 4 parts of lecithin, 2 ~ 3 parts of vitamin E.
2. the sea-buckthorn oil health care product preferred plan of the present invention is made up of the activated feedstock of following weight：Purify Seabuckthorm Seed Oil
70 parts, 22 parts of Purple Perilla Seed Oil, 4 parts of lecithin, 4 parts of vitamin E.
3. the sea-buckthorn oil health care product preferred plan of the present invention is made up of the activated feedstock of following weight：Purify Seabuckthorm Seed Oil
80 parts, 13 parts of Purple Perilla Seed Oil, 4 parts of lecithin, 3 parts of vitamin E.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610828363.3A CN107837298A (en) | 2016-09-19 | 2016-09-19 | A kind of sea-buckthorn oil health care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610828363.3A CN107837298A (en) | 2016-09-19 | 2016-09-19 | A kind of sea-buckthorn oil health care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107837298A true CN107837298A (en) | 2018-03-27 |
Family
ID=61657172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610828363.3A Pending CN107837298A (en) | 2016-09-19 | 2016-09-19 | A kind of sea-buckthorn oil health care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107837298A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112251286A (en) * | 2020-11-17 | 2021-01-22 | 江苏鸿祺生物科技有限公司 | High-quality sea-buckthorn seed oil and extraction process thereof |
| CN114081181A (en) * | 2021-11-15 | 2022-02-25 | 成都华西康健生物工程有限公司 | Food for treating hyperlipidemia, fatty liver and coronary heart disease and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1105258A (en) * | 1994-01-11 | 1995-07-19 | 胡伟利 | Soft capsule of perilla seed oil and producing process thereof |
| CN1583108A (en) * | 2004-05-26 | 2005-02-23 | 内蒙古草原兴发股份有限公司 | Health care product of hippophae rhamnoides oil |
| CN101045081A (en) * | 2006-03-30 | 2007-10-03 | 上海水产大学 | Health-care soft capsule containing perilla oil |
| CN103082296A (en) * | 2012-12-26 | 2013-05-08 | 东莞市照燕生物科技有限公司 | Dietary supplement for reducing attacking of myocardial infarction |
| CN103301194A (en) * | 2012-03-13 | 2013-09-18 | 朱凯 | Preparation technology of cold-pressed perilla seed oil capsule and its product |
-
2016
- 2016-09-19 CN CN201610828363.3A patent/CN107837298A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1105258A (en) * | 1994-01-11 | 1995-07-19 | 胡伟利 | Soft capsule of perilla seed oil and producing process thereof |
| CN1583108A (en) * | 2004-05-26 | 2005-02-23 | 内蒙古草原兴发股份有限公司 | Health care product of hippophae rhamnoides oil |
| CN101045081A (en) * | 2006-03-30 | 2007-10-03 | 上海水产大学 | Health-care soft capsule containing perilla oil |
| CN103301194A (en) * | 2012-03-13 | 2013-09-18 | 朱凯 | Preparation technology of cold-pressed perilla seed oil capsule and its product |
| CN103082296A (en) * | 2012-12-26 | 2013-05-08 | 东莞市照燕生物科技有限公司 | Dietary supplement for reducing attacking of myocardial infarction |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112251286A (en) * | 2020-11-17 | 2021-01-22 | 江苏鸿祺生物科技有限公司 | High-quality sea-buckthorn seed oil and extraction process thereof |
| CN112251286B (en) * | 2020-11-17 | 2021-05-28 | 江苏鸿祺生物科技有限公司 | Sea-buckthorn seed oil and extraction process thereof |
| CN114081181A (en) * | 2021-11-15 | 2022-02-25 | 成都华西康健生物工程有限公司 | Food for treating hyperlipidemia, fatty liver and coronary heart disease and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| EP3868219A1 (en) | Compositions comprising curcumin for muscle health | |
| CN107771946A (en) | A kind of formula milk and its production method for contributing to middle-aged and old cardiovascular and cerebrovascular health | |
| CN101473953A (en) | Fabricated food for cleaning blood and expelling toxin as well as method for processing the same and application | |
| Radhika et al. | Nutraceuticals: An area of tremendous scope | |
| Chandra et al. | Nutraceuticals: Pharmacologically active potent dietary supplements | |
| EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
| CN102379415A (en) | Antioxidant healthcare capsule and preparation method thereof | |
| CN105767999A (en) | Buccal tablet containing wall-broken ganoderma lucidum spore powder, honey and propolis and production method thereof | |
| CN101108227A (en) | Konjak extractive powder capsule | |
| Singh et al. | Nutraceuticals: a new golden era in health and disease | |
| CN107837298A (en) | A kind of sea-buckthorn oil health care product | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN107372858A (en) | A kind of purple perilla health-care hippophae rhamnoide ready-mixed oil rich in alpha linolenic acid | |
| CN102106895A (en) | Composition with function of regulating blood fat | |
| CN101194913A (en) | Natural seal oil compression biological preparation for treating hyperlipidemia and technique of preparing the same | |
| CN1262284C (en) | Health care product of hippophae rhamnoides oil | |
| CN101120750A (en) | Method for preparing ginkgo bee product | |
| Aziz et al. | Combating Metabolic Syndrome through Non-Pharmacological Strategies: A Literature Review: Combating Metabolic Syndrome | |
| US10744100B2 (en) | Compositions and methods using a polyphenol for musculoskeletal health | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| WO2019026930A1 (en) | Food composition for increasing muscle mass, muscle mass increasing agent, therapeutic agent for locomotive syndrome, therapeutic agent for sarcopenia, exercise function maintenance agent, muscle atrophy-related gene expression inhibitor, muscle protein degradation inhibitor, muscle atrophy prevention agent, muscle synthesis-related gene expression promoter, and muscle synthesis promoter | |
| CN107950928A (en) | A kind of blood fat reducing healthcare food | |
| US20240000091A1 (en) | Nutritional supplement for lactating mothers | |
| JP2017197491A (en) | Muscle enhancing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180327 |
|
| RJ01 | Rejection of invention patent application after publication |